A plasmid DNA (pDNA) template is used as the starting material for mRNA synthesis via In vitro transcription (IVT), after which the resulting purified mRNA is encapsulated into a suitable carrier ...

Good afternoon, ladies and gentlemen, and welcome everyone to the Maravai Life Sciences third-quarter 2024 earnings conference call. (Operator Instructions) I would now like to turn the call over to ...

plug and play continuous flow mRNA IVT and purification system ahead of its full commercial launch. NTxscribe is a first-of-its-kind IVT system that enables the production of RNA in a fraction of ...

Good afternoon, ladies and gentlemen, and welcome, everyone, to the Maravai LifeSciences Third Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise ...

Maravai Lifesciences Holdings, Inc. ( (MRVI) ) has released its Q3 earnings. Here is a breakdown of the information Maravai Lifesciences ...

Announces Agreement to Acquire the DNA and RNA business of Officinae Bio, Advancing Support for Innovative Nucleic Acid R&DSAN DIEGO, Calif., ...

Of note, we commenced our first mRNA contract for a customer at our Flanders2 GMP manufacturing facility, further strengthened our CleanCap® IVT capping technology patent estate with the issuance ...

Co-Hosts Seminar with mRNA CDMO Kudo Bio to Demonstrate Linea IVT Capability for Rapid mRNA Manufacturing - STONY BROOK, NY / ACCESSWIRE / September 17, 2024 /Applied DNA Sciences, Inc. (NASDAQ ...

NTx senior leadership will attend a lineup of industry conferences throughout November and December to preview its NTxscribe system ...